Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals.
about
Modulation of cardiac contractility by the phospholamban/SERCA2a regulatomeReview of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studiesGene Therapy in Cardiac Surgery: Clinical Trials, Challenges, and PerspectivesModel-specific selection of molecular targets for heart failure gene therapyGene delivery technologies for cardiac applicationsCardiovascular gene therapy for myocardial infarctionIncreased Na⁺/Ca²⁺ exchanger expression/activity constitutes a point of inflection in the progression to heart failure of hypertensive ratsAAV-mediated gene therapy for heart failure: enhancing contractility and calcium handlingObesogenic high fat western diet induces oxidative stress and apoptosis in rat heartSmall and large animal models in cardiac contraction research: advantages and disadvantagesAnti-inflammatory loaded poly-lactic glycolic acid nanoparticle formulations to enhance myocardial gene transfer: an in-vitro assessment of a drug/gene combination therapeutic approach for direct injection.Cardiac gene therapy: optimization of gene delivery techniques in vivo.The potential of adeno-associated viral vectors for gene delivery to muscle tissue.Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure.Safety and efficacy of high-dose adeno-associated virus 9 encoding sarcoplasmic reticulum Ca(2+) adenosine triphosphatase delivered by molecular cardiac surgery with recirculating delivery in ovine ischemic cardiomyopathyNeonatal gene transfer of Serca2a delays onset of hypertrophic remodeling and improves function in familial hypertrophic cardiomyopathy.Ablation of phospholamban and sarcolipin results in cardiac hypertrophy and decreased cardiac contractilityCatheter-based intramyocardial delivery (NavX) of adenovirus achieves safe and accurate gene transfer in pigs.A needleless liquid jet injection delivery method for cardiac gene therapy: a comparative evaluation versus standard routes of delivery reveals enhanced therapeutic retention and cardiac specific gene expression.Attenuation of endoplasmic reticulum stress-related myocardial apoptosis by SERCA2a gene delivery in ischemic heart disease.Loss of microRNA-106b-25 cluster promotes atrial fibrillation by enhancing ryanodine receptor type-2 expression and calcium release.Rescuing the failing heart by targeted gene transferSERCA2a gene transfer decreases sarcoplasmic reticulum calcium leak and reduces ventricular arrhythmias in a model of chronic heart failure.MRI roadmap-guided transendocardial delivery of exon-skipping recombinant adeno-associated virus restores dystrophin expression in a canine model of Duchenne muscular dystrophy.Phospholamban Ablation Using CRISPR/Cas9 System Improves Mortality in a Murine Heart Failure Model.Ameliorated stress related proteins are associated with improved cardiac function by sarcoplasmic reticulum calcium ATPase gene transfer in heart failure.Potential of gene therapy as a treatment for heart failureLiquid jet delivery method featuring S100A1 gene therapy in the rodent model following acute myocardial infarction.Gene targeting in ischemic heart disease and failure: translational and clinical studies.Gene transfer for congestive heart failure: update 2013.Current strategies for myocardial gene delivery.Myocardial gene delivery using molecular cardiac surgery with recombinant adeno-associated virus vectors in vivo.Cardiac surgical delivery of the sarcoplasmic reticulum calcium ATPase rescues myocytes in ischemic heart failureAn emerging adeno-associated viral vector pipeline for cardiac gene therapyCalcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial.SERCA2a gene therapy in heart failure: an anti-arrhythmic positive inotrope.Targeting calcium transport in ischaemic heart disease.Targeting sarcoplasmic reticulum calcium ATPase by gene therapy.Sarcoplasmic reticulum Ca(2+) ATPase as a therapeutic target for heart failure.Effect of bortezomib on the efficacy of AAV9.SERCA2a treatment to preserve cardiac function in a rat pressure-overload model of heart failure.
P2860
Q24337593-F3FF6256-B602-456B-9D54-BCB6B17C637DQ26746907-66B7A069-10DA-4D76-94D2-0A15F3554C10Q26769595-39864B55-53D8-4621-9C20-5ED4771CB94FQ26823061-33BE922E-E03A-4220-A971-2D05DD46C0EFQ26863362-A437466E-E454-4256-A28A-E765EB2FA34FQ27014770-B312F497-F91B-4568-A1B7-62D3E79B1A98Q27334762-52E5BC62-0F3E-409F-B032-B20EB616810DQ28297096-8F80D872-8475-45FA-8317-65339CD73DE2Q28573796-93474217-7706-471E-8334-990885E2BDDEQ28658055-2C37C8FB-B727-478C-8327-4FA224FF61B5Q33799315-0B6816B3-C7F4-4313-8538-AA7D4A524A55Q33832137-C560B399-FD64-4184-A1EF-E6D05444C098Q33902499-C9D38D71-B95D-4339-9623-583F52D012DFQ34195822-C13E2949-6773-482E-8661-AAE7EB7ADAFDQ34221578-5D2ED3ED-C687-4D21-8166-5D89BAF97BFAQ34313853-ADC659F7-5CAC-4D81-823E-FCFE56BEE426Q34485808-4C92DD5B-6B7B-411A-B4D5-1FF1844CE2CEQ34542255-D002AA92-AB90-4EA4-8FED-97EDBD9804C0Q34669335-6F551391-A92E-4E65-8CFC-268AADF95D2EQ34699502-B03A15BC-12F2-44AF-97BA-B11885B54CB4Q34734903-E893B531-4B64-4B50-A932-86E1D1F21E37Q34757960-CDEAFBD0-50CC-40B7-AEC9-026D9B15484DQ35057816-F3988AB4-E981-44E2-8FB6-984B0226108EQ36179776-542A5808-00AC-4AD1-90E8-FA0B2448E56FQ36228624-589BE948-0D4D-4F7A-A0CC-19E912EF382BQ36313661-C19AEFBC-D702-42DD-A9BA-319B3ECF611EQ36497159-B5E9CCE6-B137-4D60-84FD-F806F29DF1E4Q36547398-132885F6-1028-4B87-A9B5-D2496FED5665Q36617570-51675A69-627C-442F-8C58-DC68E095292EQ36698991-A4E721FB-7E13-4648-9474-C9883A96CC3DQ36931967-0169DACB-3D25-40AD-B236-C29C860230D5Q36949271-221996C8-66FF-4AA1-9F2A-3B85F94ABE04Q37076149-ADE876A7-FC14-47A4-884A-26F641A960B1Q37272838-21607ECB-CB42-4C30-818B-0E493A202814Q37364786-BD674435-B504-4C46-98A9-E6567B75CEE9Q37418216-5FEF6D0D-93EC-4BEF-9A8B-967C1A5AAAA2Q37422613-A6B091AB-6A4F-49A4-8EEE-D32781087661Q37550406-DF4CE806-8F36-4529-BD4F-53045036D1DDQ37676218-7344D3E6-FD19-4167-86B8-A8903D7DA840Q37685861-8191DC53-9960-4203-8301-731DE59A2155
P2860
Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Recirculating cardiac delivery ...... eart failure in large animals.
@en
Recirculating cardiac delivery ...... eart failure in large animals.
@nl
type
label
Recirculating cardiac delivery ...... eart failure in large animals.
@en
Recirculating cardiac delivery ...... eart failure in large animals.
@nl
prefLabel
Recirculating cardiac delivery ...... eart failure in large animals.
@en
Recirculating cardiac delivery ...... eart failure in large animals.
@nl
P2093
P2860
P356
P1433
P1476
Recirculating cardiac delivery ...... eart failure in large animals.
@en
P2093
P2860
P2888
P304
P356
10.1038/GT.2008.120
P577
2008-07-24T00:00:00Z
P5875
P6179
1008806280